08.06.2013 Views

Télécharger le document - Eurosfaire

Télécharger le document - Eurosfaire

Télécharger le document - Eurosfaire

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

16 / 17<br />

The European Framework Programme:<br />

RSL, IAI and ATCT:<br />

Improving aircraft maintenance<br />

Investment: 40 Million Euro<br />

Key Partners: Daim<strong>le</strong>r-Chrys<strong>le</strong>r, Tha<strong>le</strong>s, A<strong>le</strong>nia, SAGEM, BAE,<br />

Airbus, Marconi and others.<br />

Airlines spend some 20% of operating costs on maintenance, but<br />

it is possib<strong>le</strong> to reduce these costs. Mechanics spend some 30%<br />

of their time trying to locate malfunctions, and human errors in<br />

maintenance are responsib<strong>le</strong> for 15% of all accidents. The goal<br />

of the TATEM project is to recognize and corroborate the use of<br />

various techniques and technologies to make aircraft maintenance<br />

more efficient.<br />

Wisair: Pervasive UWB low spectral radio<br />

Investment: 37.2 Million Euro<br />

Key Partners: Motorola, Tha<strong>le</strong>s, STMicroe<strong>le</strong>ctronics, Mitsubishi,<br />

Te<strong>le</strong>phonica, France Te<strong>le</strong>com and others.<br />

Wisair is participating in the PULSERS consortium, a strategic<br />

and prestigious project of the EU's Sixth Framework. The goal<br />

is the development of ultra-wide-band technology for wire<strong>le</strong>ss<br />

communications, including technology, infrastructure, applications,<br />

regulations, locating UWB technologies and more. The project's<br />

importance has <strong>le</strong>d to the involvement of key international<br />

industries.<br />

IS-4 International:<br />

Responding to airborne threats<br />

Investment: 36 Million Euro<br />

Key Partners: Siemens, Rockwell, Airbus, BAE, Tha<strong>le</strong>s, EADS,<br />

Gali<strong>le</strong>o Avionics and others.<br />

Leading European aerospace firms have invited the Israeli IS-4 to<br />

join the SAFEE consortium, <strong>le</strong>d by the French SAGEM company.<br />

The consortium's goal is to develop new methods and technologies<br />

to improve in-flight security, particularly against terror threats. The<br />

goal of the consortium members is to ensure that every plane will<br />

comp<strong>le</strong>te its journey safely. The infrastructure under development<br />

includes sensors, communication systems and command and<br />

control systems capab<strong>le</strong> of dealing with in-flight threats.<br />

Apnano: Nanopartic<strong>le</strong>s for<br />

machine parts<br />

Investment: 19 Million Euro<br />

Key Partners: Uppsala University (Sweden), Newcast<strong>le</strong> University<br />

(UK), EADS, Rolls-Royce, the French Atomic Energy Committee<br />

and others.<br />

The Foremost Project is based upon Israeli technologies developed<br />

at the Weizmann Institute, with applications developed by Apnano,<br />

a producer of nanometric tubes and materials from non-organic<br />

compounds. These materials are exceptionally resistant to abrasion,<br />

Stories of<br />

pressure and heat, and Apnano has developed the capacity to<br />

mass produce them. The consortium examines ways to use these<br />

materials as coatings for engineering surfaces and as lubricants,<br />

to save energy and improve performance of machine parts (in<br />

aviation, automotive, energy production and heavy industry).<br />

BioKine Therapeutics: Innovative<br />

Treatments for Autoimmune Diseases<br />

Investment: 18.8 Million Euro<br />

Key Partners: Pierre and Marie Curie University (Paris), Munich<br />

University, Lodz Medical School, Novartis and others.<br />

The INNOCHEM consortium comprises a large number of research<br />

and industrial groups focusing on new chemo-kine-based treatments<br />

for autoimmunity and chronic inflammation. After five years,<br />

clinical trials will be held. BioKine is located in Rehovot.<br />

Theravir and the Hebrew University:<br />

Advancing Genetics in Medicine<br />

Investment: 18 Million Euro<br />

Key Partners: Bologna Technological Institute, The Czech Institute<br />

for Mo<strong>le</strong>cular Genetics, Ulm University (Germany), and others.<br />

The CLINIGENE consortium was founded with the aim of<br />

establishing a European network of researchers and industrialists<br />

in medical genetic research. The shared goal is to advance gene<br />

therapy through the development of safe and reliab<strong>le</strong> systems.<br />

The network also focuses on gene transfer and the integration of<br />

studies and multidisciplinary developments in the treatment and<br />

mobilization of genes. A full range of organizations are involved<br />

in developing genetically based medical products and treatments.<br />

These include academia, industry, regulatory bodies, clinics and<br />

hospitals.<br />

Technion and ColorChip: Nanometric<br />

Structures<br />

Investment: 16.7 Million Euro<br />

Key Partners: Fraunhofer, Phillips, Carl Zeiss (Germany), the<br />

French Atomic Energy Committee and others.<br />

The CHARPAN consortium advances innovative technology in<br />

processing materials through multip<strong>le</strong> ion beams, developed by<br />

the Austrian IMS company. The technology has many potential<br />

applications, among them: production of camera micro-<strong>le</strong>nses to<br />

creating templates for nano-etching technology, fabrication of<br />

biological and chemical components for nano-labs and improving<br />

the production process for e<strong>le</strong>ctronic components. The aim is<br />

to develop solutions for the production of minuscu<strong>le</strong>, comp<strong>le</strong>x<br />

three-dimensional templates with precision at a nanometric <strong>le</strong>vel.<br />

A follow-up project, involving the Technion in operation.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!